Desogestrel
Active form: Etonogestrel.
JFDA label: Cerazette tab
Mechanism of Action
Agonist of Progesterone receptor — Progesterone receptor agonist
| Target | Action | Gene / class |
|---|---|---|
| Progesterone receptor efficacy | AGONIST | PGR |
Indications
Off-label
- Amenorrhea
- Hemorrhage
- Infertility
- Polycystic Ovary Syndrome
- Sleep Apnea, Central
Adverse Reactions
Vascular disorders (1)
Not Known Hypertension
Nervous system disorders (2)
Not Known Headache · Migraine
Hepatobiliary disorders (1)
Not Known Hepatic neoplasm
Immune system disorders (2)
Not Known Hypersensitivity · Immune system disorder
Metabolism and nutrition disorders (1)
Not Known Fluid retention
Gastrointestinal disorders (6)
Not Known Abdominal pain · Diarrhoea · Gastrointestinal disorder · Gastrointestinal pain · Nausea · Vomiting
Skin and subcutaneous tissue disorders (7)
Not Known Alopecia · Dermatitis · Erythema multiforme · Erythema nodosum · Rash · Skin disorder · Urticaria
Psychiatric disorders (5)
Not Known Depressed mood · Libido decreased · Libido increased · Mental disorder · Mood swings
Eye disorders (1)
Not Known Eye disorder
Reproductive system and breast disorders (7)
Not Known Breast cancer · Breast discharge · Breast disorder · Breast enlargement · Breast pain · Breast tenderness · Vaginal discharge
Investigations (2)
Not Known Weight decreased · Weight increased
General disorders and administration site conditions (8)
Not Known Affect lability · Cataract · Chloasma · Contact lens intolerance · Disturbance in sexual arousal · Hirsutism · Malnutrition · Nervous system disorder
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (1)
Not Known Neoplasm
Pregnancy & Lactation
Pregnancy
Lactation
Expert opinion holds that the risks of progestin-only contraceptive products usually are acceptable for nursing mothers at any time postpartum. For further information, consult the record entitled, Contraceptives, Oral, Combined .
Chemistry & Properties
| Formula | C22H30O |
|---|---|
| Molecular weight | 310.48 g/mol |
| IUPAC name | (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol |
| CAS | 54024-22-5 |
| PubChem CID | 40973 |
| InChIKey | RPLCPCMSCLEKRS-BPIQYHPVSA-N |
| logP | 4.87 (XLogP 4.9) |
| Polar surface area | 20.23 Ų |
| H-bond acceptors / donors | 1 / 1 |
| Drug-likeness (QED) | 0.54 |
| Lipinski violations | 0 |
SMILES
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CCBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|---|
| Half-life | 2.45 h |
| Volume of distribution | 2.747 L/kg |
| Protein binding | 97.1% |
| BBB penetrant | No |
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2B6 | Inhibitor | — |
| CYP2C19 | Inhibitor | — |
| CYP2C19 | Substrate | — |
| CYP2C8 | Inhibitor | — |
| CYP3A4 | Inhibitor | — |
| CYP3A4 | Substrate | — |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Drug–drug interactions (43, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Bexarotene | major | |
| Dabrafenib | major | |
| Sugammadex | major | |
| Adalimumab | moderate | |
| Albiglutide | moderate | |
| Alefacept | moderate | |
| Alogliptin | moderate | |
| Aprepitant | moderate | |
| Certolizumab pegol | moderate | |
| Dapagliflozin | moderate | |
| Deferasirox | moderate | |
| Ertugliflozin | moderate | |
| Glycerol phenylbutyrate | moderate | |
| Infliximab | moderate | |
| Insulin aspart (aspart protamine) | moderate | |
| Insulin aspart (aspart) | moderate | |
| Insulin degludec | moderate | |
| Insulin detemir | moderate | |
| Insulin glulisine | moderate | |
| Insulin human (zinc) | moderate | |
| Insulin lispro (protamine) | moderate | |
| Ivacaftor | moderate | |
| Lapatinib | moderate | |
| Linagliptin | moderate | |
| Liraglutide | moderate | |
| Lixisenatide | moderate | |
| Metformin | moderate | |
| Metreleptin | moderate | |
| Miltefosine | moderate | |
| Nateglinide | moderate | |
| Neratinib | moderate | |
| Pegaspargase | moderate | |
| Rilonacept | moderate | |
| Rosiglitazone | moderate | |
| Sarilumab | moderate | |
| Saxagliptin | moderate | |
| Secukinumab | moderate | |
| Siltuximab | moderate | |
| Sitagliptin | moderate | |
| Tocilizumab | moderate |
Showing 40 of 43.
Registered Products (7)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Violet E | Tablet 0.03 mg, 0.15 mg | 21 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 1.900 |
| Violet F.C.T | Tablet 75 mcg | 28 tab | Dar Al Dawa Development and Investment Co Ltd/Jordan | 2.280 |
| ZYNOGEST | Tablet Desogestrel 0.075 mg | (28 UNT) / BLISTERS | Noor Drug Store | 2.480 |
| Perla | Tablet 0.075 mg | 28 tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.600 |
| Desirett | Tablet 75 mcg | 28 tab | Nairoukh Drug Store | 2.670 |
| MARVELON TABS | Tablet 0.030 mg, 0.15 mg | 21 tab | Sabbagh Drug Store | 2.720 |
| Cerazette tab | Tablet 0.075 mg | 28 tab | Sabbagh Drug Store | 3.810 |